Using the DEN model of hepatocarcinogenesis in mice Jeric and colleagues describe an unexpected anti-proliferative role of RAF1 in HCC development. Downregulation of RAF by RNA interference or genetic loss of RAF1 in vivo promotes hepatocellular tumor cell growth. The authors propose that this pro-tumorigenic phenotype in the absence of RAF function is linked to an upregulation of gp130-dependent Stat3 activation and YAP1 upregulation. Pharmacological Stat3 inhibition and YAP1 knockdown revert the elevated proliferation in RAF1 deficient cells. This is a very interesting and very well performed study that may have great impact for our understanding and the treatment of human disease. I only have two minor points that should be considered. 1. Recently, it was suggested in intestinal epithelial cells that gp130 triggers YAP1 activation independently of STAT3 via Src and Yes. In the manuscript here only a pharmacological Stat3 inhibitor was used, however, it was not addressed whether increased YAP1 expression could be linked to gp130 as well. Thus, it would be nice if the authors could provide evidence using if siRNA mediated knockdown of gp130 in Raf1 deficient cells that YAP1 is downstream of gp130 or not. 2. To corroborate the potential importance for human diseases and sorafenib treatment in human patients, the manuscript would benefit if the authors could examine whether the phenotype proposed here -particularly gp130 and YAP1 upregulation-can be found in sorafenib treated patients or at least in the mouse models used in this study. Presumably it will be important to compare the effects of sorafenib in vitro and in vivo considering that concomitant loss of Raf1 in hepatocytes and hematopoeitic cells shows a milder phenotype than deletion in hepatocytes only, suggesting that RAF1 inhibition in myeloid cells may actually be tumorsuppressive.
Reviewer #2 (Remarks to the Author):
The manuscript by Jeric et al. reveals a robust and unanticipated contribution of RAF1 to tissue homeostasis via support of HIPPO pathway activity. The phenotypes in mice are significant and convincing. The cell biology confirms cell autonomous effects. Overall, the manuscript represents an important body of work that should be shared with the community at large. I have a few suggestions:
1. Impact: can the investigators inform the audience more effectively with respect to the overarching relevance of the observations? I.e.-is the mechanistic relationship at the molecular level generalizable to all tissues/cell types, with selective consequences or is there tissue/cell type selective mechanistic coupling of Raf1 and YAP? Related to this, in the tumors the authors describe as RAF1 dependent (lung?) -I think there is evidence that YAP1 activation is a targeted therapy resistance mechanism. Does this suggest the relationships shown in this paper are independent of RAF1 kinase activity? 2. Mechanism: this work is a genetic tour-de-force, however, some straight-forward molecular relationships could be pursued with the material at hand. I.e. potential roles of RASSF1A and/or unanticipated participation of Raf1 in MST1/2 activation? 3. RNAi: Many shRNA and siRNA experiments appear to be performed with a single reagent. RAF1 is well covered by orthoganol approaches. YAP1 is not
NCOMMS-16-14452 -Point-by-point reply
Reviewer #1 (Remarks to the Author):
Reviewer is very appreciative of our work, which s/he predicts to have a great impact for our understanding of hepatocarcinogenesis.
The Reviewer has only two minor points:
1. "it would be nice if the authors could provide evidence using if siRNA mediated knockdown of gp130 in Raf1 deficient cells that YAP1 is downstream of gp130 or not". Sorafenib (Horwitz et al., 2014) . Supplementary Fig. 7 .
The GP130 KD was performed in DIH and

Therefore the experiments in vivo, besides being extremely time-consuming and involving animal suffering, are not likely to yield conclusive or readily interpretable results; it is also impossible for us to obtain access to a patient cohort and analyze it within the time allotted for revision. As proof of principle, we have treated premalignant DIH with a range of inhibitors: a specific RAF inhibitor (GDC-0879) and with Sorafenib. The results show that neither complete inhibition of RAF kinase activity by GDC-0879 nor paradox ERK activation by Sorafenib increase YAP1 or GP130 expression. Both Sorafenib and GDC reduced the proliferation of DIH, but GDC was less efficient in RAF1-deficient cells. The data are shown in
We hope that the reviewer will bear with us on this point.
Reviewer #2 (Remarks to the Author):
This Reviewer is also appreciative of the manuscript's novelty and importance. S/he has a few suggestions: Supplementary Fig. 6 .
1b. "in the tumors the authors describe as RAF1-dependent (lung?) -I think there is evidence that YAP1 activation is a targeted therapy resistance mechanism. Does this suggest the relationships shown in this paper are independent of RAF1 kinase activity?"
The reviewer is probably referring to the paper by Lin et al. (Nature Genetics 2015, 47:250-256) Supplementary Fig. 7 ).
2. "some straight-forward molecular relationships could be pursued with the material at hand. I.e. potential roles of RASSF1A and/or unanticipated participation of Raf1 in MST1/2 activation"? (Kittler et al., 2007, Nat. Methods 4, 337-344,) (Zhou et al. 2009, Cancer Cell 16:425-38; Fitamant et al. 2015 , Cell Reports, 10:1692 -1707 Su et al. 2015, eLife, 4:e02948) , providing independent confirmation of our data. We thus hope that the reviewer will bear with us on this point.
